Cytochrome P450 and therapeutic drug monitoring with respect to clozapine
- 1 December 1999
- journal article
- review article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 9 (6) , 453-459
- https://doi.org/10.1016/s0924-977x(99)00033-4
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath testBritish Journal of Clinical Pharmacology, 1998
- Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humansBritish Journal of Clinical Pharmacology, 1997
- Will Routine Therapeutic Drug Monitoring Have a Place in Clozapine Therapy?Clinical Pharmacokinetics, 1997
- Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detectionBiomedical Chromatography, 1995
- Pharmacokinetics and Pharmacodynamics of ClozapineClinical Pharmacokinetics, 1993
- Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactionsNordic Journal of Psychiatry, 1993
- Mechanisms of Clozapine†-Induced AgranulocytosisDrug Safety, 1992
- Clinical pharmacokinetics of clozapine in chronic schizophrenic patientsEuropean Journal of Clinical Pharmacology, 1988
- Determination of clozapine and its metabolites in serum and urine by reversed phase HPLCBiomedical Chromatography, 1986
- Drug-Induced Aplastic Anaemia and AgranulocytosisDrugs, 1986